A multimodal approach for establishing <i>ACTL6A</i> and <i>ERCC1</i> as chemoresistance genes in locally advanced head and neck cancer.

ABSTRACT:

Background

DNA is generally considered the ultimate target of cisplatin, so DNA repair has become the hallmark for cisplatin chemoresistance that is attributed to the poor overall survival (50%) among patients with head and neck cancer (HNC). As the efficacy of cisplatin is dose-dependent, we conducted the first study in an Asian population to characterize the DNA repair genes ACTL6A and ERCC1 based on the dosing of cisplatin-based chemoradiotherapy (CRT).

Methods

Locally advanced HNC (LAHNC) patients who were planning to undergo cisplatin-based CRT were enrolled in a prospective study to quantify the dose-dependent expressions of ACTL6A and ERCC1 from peripheral blood mononuclear cells via quantitative polymerase chain reaction; these results wer

SUBMITTER: Chaudhary RK 

PROVIDER: S-EPMC12159016 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature